Unicycive Therapeutics, Inc. (UNCY) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Los Altos, CA, アメリカ. 現CEOは Shalabh K. Gupta.
UNCY を有する IPO日 2021-07-12, 22 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $149.15M.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
